Analytical Data
-
Gene name
SLC1A3
- Application
-
Alternative Names
Sodium-dependent glutamate/aspartate transporter 1;GLAST-1;Solute carrier family 1 member 3
-
Species
Human
-
Source
E. coli
-
Tag
N- His-KSI
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43003
-
Expression Region
146-236aa
-
Molecular Weight
25.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC1A3, also known as EAAT1 (excitatory amino acid transporter 1), is a crucial glutamate transporter predominantly expressed in astrocytes within the central nervous system. It plays a vital role in maintaining glutamate homeostasis, preventing excitotoxicity, and regulating neurotransmission. Dysregulation of SLC1A3 has been implicated in various neurological disorders, including epilepsy, Alzheimer's disease, and Huntington's disease. The study of SLC1A3 is essential for understanding its functional mechanisms and potential as a therapeutic target. The recombinant expression of SLC1A3 in heterologous systems allows for detailed structural and functional characterization, facilitating the exploration of its substrate binding and transport properties. Advances in recombinant protein technology, such as the use of eukaryotic expression systems, have enabled researchers to produce functional and properly folded SLC1A3 proteins, advancing our understanding of its role in neurobiology. Additionally, structural studies, including X-ray crystallography and cryo-electron microscopy, are paving the way for insights into the transport cycle and the transporter's interaction with different ligands, potentially informing drug design aimed at modulating its activity. Overall, the research on SLC1A3 recombinant protein not only provides valuable information about glutamate transport but also opens avenues for novel therapeutic approaches in neurodegenerative and psychiatric disorders.
